Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Fontana, L., Partridge, L
doi: 10.1136/gut.48.2.206 51
This patient-driven momentum is reshaping treatment paradigms, pushing manufacturers like Novo Nordisk and Eli Lilly to prioritize the development of oral versions that enhance adherence and overall user experience, transforming how diabetes and weight management are approached
This update is crucial for manufacturers, regulators, and quality professionals as it: aligns Indian standards with global practices strengthens quality control and compliance improves confidence in Indian medicines worldwide Quality frameworks like the IP quietly shape the future of Indian pharma
US$ 27.34
US$ 20.78
US$ 25.66
US$ 24.71
US$ 27.10
